CervoMed's neflamapimod selected for UK EXPERTS-ALS platform for ALS trial

CervoMed Inc.

Neflamapimod will be evaluated in EXPERTS-ALS, funded by UK NIHR and motor neuron disease charities, costs covered externally.
Initial phase: ~35 ALS patients for 18-24 weeks measuring neurofilament light chain (NfL) biomarker; potential expansion to 80.
First patient with ALS expected to be dosed by end of 2026; trial sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.
CervoMed maintains primary focus on dementia with Lewy bodies (DLB); Phase 3 in DLB planned to start later in 2026.
Inclusion based on neflamapimod's p38 inhibition, ability to cross BBB, and positive prior clinical safety/biomarker data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.